Intrinsic Value of S&P & Nasdaq Contact Us

Zoetis Inc. ZTS NYSE

NYSE • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
71/100
4/7 Pass
SharesGrow Intrinsic Value
$130.84
+8%
Analyst Price Target
$143.86
+18.8%

Zoetis Inc. (ZTS) generated $893M in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $161M, free cash flow was $732M.

Free cash flow margin was 30.7% of revenue. Cash conversion ratio was 1.48x, indicating earnings are backed by cash.

The company returned $220M in dividends and $2.06B in share buybacks to shareholders during the quarter.

Criteria supported by this page:

  • HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
  • MOAT (76/100, Pass) — $732M (30.7% margin) supports a durable competitive advantage
  • INCOME (85/100) — Cash conversion ratio was 1.48x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 71/100 with 4/7 criteria passed.

SharesGrow 7-Criteria Score
71/100
SG Score
View full scorecard →
~
VALUE
48/100
Price-to-Earnings & upside
→ Valuation
~
FUTURE
58/100
Analyst consensus
→ Forecast
PAST
100/100
→ Income
~
HEALTH
67/100
Debt-to-Equity & liquidity
Proven by this page
MOAT
76/100
Proven by this page
GROWTH
65/100
→ Income
INCOME
85/100
→ Income
Zoetis Inc. Cash Flow History
Metric TTM Q4 FY2025 Q3 FY2025 Q2 FY2025 Q1 FY2025
Operating Cash Flow $2.9B$893M$938M$486M$587M
Capital Expenditure $-621M$-161M$-133M$-178M$-149M
Free Cash Flow $2.28B$732M$805M$308M$438M
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message